From 2024 to 2028, sales of systemic hormonal preparations in Italy, excluding sex hormones and insulins, are forecasted to slightly decline. Starting from a 2% share of total sales in 2024, a gradual decrease to 1.8% is anticipated by 2028. Compared to actual figures from 2023, this represents a reduction. Year-on-year, there is a consistent decrease between 0-5%, reflecting a steady downtrend without abrupt changes. The cumulative average growth rate (CAGR) indicates a small but steady decline over this forecast period.
Future trends to watch include potential shifts in medical guidelines, new therapeutic developments, and economic factors affecting healthcare budgets. Additionally, monitoring demographic changes and patient preferences will be pivotal in discerning future demand for systemic hormonal treatments in Italy.
